Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | CALCA | P06881 | 1/20 | 0.39 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204736 | 0.93 | CYP2C9 (0.50) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL2208862 | 0.91 | KCNH2 (0.45) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL2206750 | 0.88 | KCNH2 (0.49) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL2206416 | 0.87 | KCNH2 (0.48) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL2206415 | 0.86 | KCNH2 (0.47) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL2204728 | 0.85 | CYP2C9 (0.53) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL2204703 | 0.85 | KCNH2 (0.48) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL2202493 | 0.84 | KCNH2 (0.46) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL2205620 | 0.84 | KCNH2 (0.51) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL2205267 | 0.84 | KCNH2 (0.51) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | claimed |
| EP-1866313-A1 | HIV INTEGRASE INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2007-12-19 | — | — | EP | claimed |
| WO-2006103399-A1 | HIV INTEGRASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2006-10-05 | — | — | WO | claimed |
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | SUMMA VINCENZO | 2011-10-20 | — | — | US | disclosed |
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | SUMMA VINCENZO | 2011-10-20 | — | — | US | disclosed |
| US-7981879-B2 | HIV integrase inhibitors | Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2011-07-19 | — | — | US | disclosed |
| US-7981879-B2 | HIV integrase inhibitors | Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2011-07-19 | — | — | US | disclosed |
| US-7981879-B2 | HIV integrase inhibitors | Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2011-07-19 | — | — | US | disclosed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | disclosed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | disclosed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | REV1, CDK9, INTS9 | KCNH2 2918/4885CYP2C9 672/4885SMN1; SMN2 2699/4885 |
| US-20090253681-A1 | HIV Integrase Inhibitors | REV1, INTS9, H1-10 | KCNH2 3625/4885CYP2C9 449/4885SMN1; SMN2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.